Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, open-label, multicenter study to evaluate the safety and anti-tumor efficacy of AZD4205 in subjects with peripheral T-cell lymphoma who had tumor remission after first-line systemic therapy

Next Previous
Search
Trial Profile

A Phase II, open-label, multicenter study to evaluate the safety and anti-tumor efficacy of AZD4205 in subjects with peripheral T-cell lymphoma who had tumor remission after first-line systemic therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golidocitinib (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Acronyms JACKPOT26
  • Sponsors Dizal Pharmaceutical

    • Most Recent Events

    • 19 Jul 2024 Status changed from planning to active, no longer recruiting.
    • 12 Dec 2023 Results (As of June 27, 2023, n=48) assessing antitumor efficacy and safety of golidocitinib as maintenance treatment after first-line therapy presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results presented in a Dizal Pharmaceutical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top